{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TBL+12&page=17",
    "query": {
      "intervention": "TBL 12",
      "page": 17
    },
    "page_size": 10
  },
  "pagination": {
    "page": 17,
    "page_size": 10,
    "total_count": 1228,
    "total_pages": 123,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TBL+12&page=18&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TBL+12&page=16&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-04T05:52:27.265Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03092375",
      "title": "Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis C",
        "HCV"
      ],
      "interventions": [
        {
          "name": "Glecaprevir/Pibrentasvir (G/P) 300mg/120mg",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin 200Mg Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 177,
      "start_date": "2017-04-20",
      "completion_date": "2020-02-06",
      "has_results": true,
      "last_update_posted_date": "2020-02-26",
      "last_synced_at": "2026-11-04T05:52:27.265Z",
      "location_count": 31,
      "location_summary": "Palo Alto, California • San Francisco, California • Washington D.C., District of Columbia + 22 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03092375"
    },
    {
      "nct_id": "NCT02412111",
      "title": "A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "Ivacaftor",
          "type": "DRUG"
        },
        {
          "name": "Tezacaftor/Ivacaftor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 156,
      "start_date": "2015-06",
      "completion_date": "2017-09",
      "has_results": true,
      "last_update_posted_date": "2019-01-08",
      "last_synced_at": "2026-11-04T05:52:27.265Z",
      "location_count": 33,
      "location_summary": "Birmingham, Alabama • Oakland, California • San Diego, California + 30 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02412111"
    },
    {
      "nct_id": "NCT01093534",
      "title": "Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Detrusor Overactivity",
        "Overactive Bladder"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "solifenacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 547,
      "start_date": "2010-01-19",
      "completion_date": "2011-06-23",
      "has_results": true,
      "last_update_posted_date": "2024-12-03",
      "last_synced_at": "2026-11-04T05:52:27.265Z",
      "location_count": 3,
      "location_summary": "New York, New York • West Reading, Pennsylvania",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "West Reading",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01093534"
    },
    {
      "nct_id": "NCT00302952",
      "title": "Lovastatin for the Treatment of Mildly Active Rheumatoid Arthritis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Lovastatin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 64,
      "start_date": "2007-11-06",
      "completion_date": "2012-04-30",
      "has_results": true,
      "last_update_posted_date": "2022-09-07",
      "last_synced_at": "2026-11-04T05:52:27.265Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Lansing",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00302952"
    },
    {
      "nct_id": "NCT01797120",
      "title": "Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PrECOG, LLC.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 131,
      "start_date": "2013-05-31",
      "completion_date": "2017-09-12",
      "has_results": true,
      "last_update_posted_date": "2018-05-30",
      "last_synced_at": "2026-11-04T05:52:27.265Z",
      "location_count": 25,
      "location_summary": "Greenbrae, California • Stanford, California • Rockford, Illinois + 21 more",
      "locations": [
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Rockford",
          "state": "Illinois"
        },
        {
          "city": "Ames",
          "state": "Iowa"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01797120"
    },
    {
      "nct_id": "NCT02909959",
      "title": "Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autism Spectrum Disorder",
        "Autistic Disorder",
        "Neurodevelopmental Disorder",
        "Childhood Developmental Disorders, Pervasive"
      ],
      "interventions": [
        {
          "name": "Sulforaphane",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "30 Years",
        "sex": "MALE",
        "summary": "13 Years to 30 Years · Male only"
      },
      "enrollment_count": 48,
      "start_date": "2017-03-01",
      "completion_date": "2019-05-30",
      "has_results": true,
      "last_update_posted_date": "2020-06-04",
      "last_synced_at": "2026-11-04T05:52:27.265Z",
      "location_count": 1,
      "location_summary": "Carrboro, North Carolina",
      "locations": [
        {
          "city": "Carrboro",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02909959"
    },
    {
      "nct_id": "NCT00235755",
      "title": "Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Seizures"
      ],
      "interventions": [
        {
          "name": "Retigabine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 539,
      "start_date": "2005-12",
      "completion_date": "2008-04",
      "has_results": true,
      "last_update_posted_date": "2017-04-21",
      "last_synced_at": "2026-11-04T05:52:27.265Z",
      "location_count": 2,
      "location_summary": "Bethesda, Maryland • Dallas, Texas",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00235755"
    },
    {
      "nct_id": "NCT07342491",
      "title": "Dasatinib for HIV-1 Reservoir Reduction",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Dasatinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2026-05-08",
      "completion_date": "2027-09-24",
      "has_results": false,
      "last_update_posted_date": "2026-10-27",
      "last_synced_at": "2026-11-04T05:52:27.265Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • Cleveland, Ohio • Seattle, Washington",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07342491"
    },
    {
      "nct_id": "NCT01099618",
      "title": "Ketosis-Prone Diabetes Mellitus (KPDM): Metformin Versus Sitagliptin Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Ketosis Prone Diabetes",
        "Diabetes Ketoacidosis",
        "Hyperglycemia"
      ],
      "interventions": [
        {
          "name": "metformin",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "Sitagliptin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dawn Smiley MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "19 Years to 65 Years"
      },
      "enrollment_count": 48,
      "start_date": "2010-03",
      "completion_date": "2014-08",
      "has_results": true,
      "last_update_posted_date": "2015-06-18",
      "last_synced_at": "2026-11-04T05:52:27.265Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01099618"
    },
    {
      "nct_id": "NCT03938246",
      "title": "Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)"
      ],
      "interventions": [
        {
          "name": "TVB-2640 25 mg (US)",
          "type": "DRUG"
        },
        {
          "name": "TVB-2640 50 mg (US)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (US)",
          "type": "DRUG"
        },
        {
          "name": "TVB-2640 50 mg (China)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (China)",
          "type": "DRUG"
        },
        {
          "name": "TVB-2640 75 mg (US)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sagimet Biosciences Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 142,
      "start_date": "2019-03-22",
      "completion_date": "2021-10-02",
      "has_results": true,
      "last_update_posted_date": "2024-12-19",
      "last_synced_at": "2026-11-04T05:52:27.265Z",
      "location_count": 12,
      "location_summary": "Chula Vista, California • Montclair, California • Sacramento, California + 9 more",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Montclair",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03938246"
    }
  ]
}